After this evening's 3.0% surge to $338.22 per share, Amgen might just keep moving past its target price of $352.23. With an average analyst rating of buy, and target prices from $200.0 to $427.0, the stock's next move is anyone's guess.
The stock has an average amount of shares sold short at 2.3%, and a short ratio of 4.6. The company's insiders own 0.22% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.3% of Amgen's shares being owned by this investor type.
Institutions Invested in Amgen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2026-03-31 | Blackrock Inc. | 9% | 47,100,472 | $15,930,321,697 |
| 2026-03-31 | Vanguard Capital Management LLC | 6% | 35,014,232 | $11,842,513,589 |
| 2026-03-31 | State Street Corporation | 6% | 30,548,488 | $10,332,109,648 |
| 2026-03-31 | Capital World Investors | 5% | 29,288,343 | $9,905,903,405 |
| 2026-03-31 | Morgan Stanley | 3% | 15,836,058 | $5,356,071,556 |
| 2026-03-31 | Geode Capital Management, LLC | 3% | 15,430,524 | $5,218,911,846 |
| 2026-03-31 | Vanguard Portfolio Management LLC | 3% | 14,621,148 | $4,945,164,694 |
| 2026-03-31 | Charles Schwab Investment Management, Inc. | 2% | 12,773,386 | $4,320,214,628 |
| 2026-03-31 | Primecap Management Company | 2% | 8,874,129 | $3,001,407,921 |
| 2026-03-31 | JPMORGAN CHASE & CO | 1% | 7,277,837 | $2,461,510,039 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Amgen.
